| Primary reference | The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease., Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Luond RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C, EMBO Mol Med. 2018 Sep 17. pii: emmm.201809316. doi: 10.15252/emmm.201809316. PMID:30224383 |